Building a ‘Swiss Army Knife’ longevity drug
LinkGevity, a Cambridge-based longevity biotech, is developing a first-in-class anti-necrotic small molecule to inhibit necrosis. The company reports preclinical data showing 90–100% cell survival in stressed assays and positions necrosis inhibition as a potential multi-disease, system-wide geroprotective strategy.
Why it mattersAnti-necrotic small-molecule showed 90–100% cell survival in stressed assays; prioritize confirming reproducibility and IND pathway.
People Mentioned
Carina Kern